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Available online 29 December 2015Tuberculosis (TB) remains as a global health problem. The prevalence of this infection is related to the association
with other diseases, such as HIV, neglect treatment and misuse of antibiotics. Hence, the identiﬁcation of new
drugs is required to eradicate TB. Possible alternatives to existing antibiotics include pure compounds extracted
from medicinal plants, which are an important source of antimicrobial agents. The aim of this study was to
evaluate the effect of nordihydroguaiaretic acid (NDGA) andα-mangostin onMycobacterium tuberculosis growth
and bacterial survival in infected macrophages derived from the human THP-1 cell line and monocytes. Our
results show that both compounds directly inhibit M. tuberculosis growth in liquid medium with Minimal
Inhibitory Concentrations (MIC) of 250 and 62 μg/mL respectively, likely through preventing bacterial replica-
tion. In addition, NDGA andα-mangostin were able to induce autophagy in human cells at lower concentrations
(7 and 6 μg/mL, respectively) and contributed to the elimination of intracellular bacteria. NDGAandα-mangostin
could be candidates for coadjuvant therapy in cases of drug-resistant TB, and their ability to enhance the immune
response by promoting autophagy might contribute to TB treatment.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Autophagy1. Introduction
Tuberculosis (TB) is caused by Mycobacterium tuberculosis and
remains a global health problem. It is estimated that 9.0 million people
developed this infection and 1.5 million died from TB in 2013 (WHO,
2014). The prevalence of TB is related to neglect treatment and the
misuse of drugs as well as patient complications from other diseases,
such as diabetes mellitus and HIV [1].
In the last decade, there has been a renewed of focus on the develop-
ment of drugs to treat TB, and several compounds are evaluated in
clinical trials (WHO, 2013). However, despite the small but growing
number of drugs that are effective at killingM. tuberculosis, the current
treatment is still burdened by its duration (typically 6 months for drug-
sensitive strains) and the ever-increasing number of multidrug-
resistant (MDR) and extensively drug-resistant (XDR) clinical isolates
ofM. tuberculosis [2].
Antibiotic resistance now represents a devastating problem for
human health because pathogens have developed mechanisms to
evade all available antibiotics [3]. Thus, the development of newción en Microbiología, Instituto
pan 4502, Sección XVI, México
s).
. This is an open access article underantimicrobial agents and strategies for the treatment of TB are funda-
mental for its eradication.
The existing drugs used for treating TB primarily target metabolic
reactions and proteins that are essential for the active growth of
M. tuberculosis [4]. Currently, the search is focused on ﬁnding new
drugs that can act on molecular targets related to the establishment of
mycobacterial dormancy in human macrophages or inhibit bacterial
virulence factors that interfere with the signaling pathways of host
cells and affect their immunocompetence, leading to the persistence of
the disease [5].
One way to develop new drugs is by studying the biological activity
of natural products, semi-synthesis or the generation of new com-
pounds [6–9]. The great diversity of natural compounds represents a
powerful tool for drug discovery; such compounds could be applied,
as new drugs with potential antimicrobial activity themselves or by
a modulating the immune response to enhance the removal of the
infective agent [10].
Larrea tridentata and Garcinia mangostana are widely used to treat
diverse diseases, including infectious diseases such as inﬂuenza, ﬂu
and even TB [11–14]. It has been experimentally demonstrated that
extracts from L. tridentata and G. mangostana show bactericidal activity
against strains ofM. tuberculosis [13,15,16].
Research on L. tridentata has shown that this species is a remarkable
source of bioactive compounds. The resin covering its leaves contains 19
ﬂavonoid aglycones as well as several lignans, including NDGA [17]. Athe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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alkaloids have been isolated from the bark and roots. Among the most
abundant compounds found in L. tridentata is NDGA. This compound ac-
counts for between 5 and 10% of the total dryweight of the leaves and is
themost abundant phenol resin (N80%) [11,17]. Extensive studies have
shown that NDGA presents beneﬁcial properties, including antioxidant,
antitumor, antiviral, antibacterial and anti-inﬂammatory activity [12,
18].
NDGA has been demonstrated to selectively inhibit arachidonic acid
5-lipoxygenase activity, which in turn reduces leukotriene and prosta-
glandin synthesis, thus leading to a reduction of inﬂammatory activity.
NDGA also has profound effects on the secretory pathway, reﬂected in
its ability to block the production of leukotriene B4, degranulation,
phagocytosis, and the respiratory burst [19]. Furthermore, NDGA
reduces cytokine production, including that of IL-4, IL-5, IL-13, and
TNF-α in human cell lines and murine models [20].
In addition, the pericarp of G. mangostana has a wide diversity of
compounds as xanthones, benzophenones, bioﬂavonoids and
triterpenes [21–23]. The α-mangostin is the most abundant xanthone
ofG.mangostana; it yields 30–50% frompericarp [16,24]. Several studies
have shown that α-mangostin has remarkable biological activities as
antioxidant, antitumoral, anti-inﬂammatory, antiallergy, antibacterial,
antifungal and antiviral [14]. Recently, it was demonstrated that α-
mangostin selectively induced autophagy in chronic myeloid leukemia
(CML) cell lines and human glioblastoma cells [25,26]. α-Mangostin
increases the expression level of the autophagosome markers Beclin1
and LC-3II, and promote the accumulation of autophagic vesicles [26].
In this study, the objectivewas to evaluate the effect of NDGA andα-
mangostin on the survival of M. tuberculosis H37Ra in vitro and the
intracellular survival of bacteria in infected THP-1 cells and in human
monocyte derived macrophages (MDMs).
2. Materials and methods
2.1. Reagents
NDGA orα-mangostin was dissolved in dimethyl sulfoxide (DMSO),
all of these were purchased from Sigma-Aldrich (St. Louis, MO, USA)
to a concentration of 20 mg/mL and then further diluted in culture
media. Autophagy inhibitors SB 203580 (SB) were acquired from
Promega (Madison, WI, USA) and Wortmannin from Calbiochem
(USA). NDGA and α-mangostin were lipopolysaccharide (LPS) free as
determined by Limulus Amebocyte Lysate Pyrogent 03 assay kit
(Lonza, Walkersville, MD, USA).
2.2. Bacterial culture conditions
M. tuberculosis H37Ra was purchased from the American Type
Culture Collection (ATCC 25177, Rockville, MD, USA). It was routinely
grown at 37 °C in 7H9 broth (Difco, Detroit, MI, USA) supplemented
with ADC (Beckton Dickinson, BD, San Jose, CA, USA) and 0.2% glycerol
or on solid Middlebrook 7H10 medium (Difco) supplemented with
0.5% glycerol and OADC (BD). We also used a strain of M. tuberculosis
H37Ra that contains the pCherry8 plasmid (Plasmid number 24663,
provided by Addgene, Cambridge, MA, USA). This plasmid expresses
the ﬂuorescent reporter protein mCherry from the Psmyc promoter
[27].M. tuberculosisH37Rawas transformedwith the pCherry8 plasmid
via electroporation [28]. Then, the bacteria were grown in 7H9
Middlebrook medium supplemented with OADC, 0.05% Tween-80
(Sigma-Aldrich), and 50 μg/mL hygromycin B (Roche Life Science,
Indianapolis, IN, USA). Prior to infection, M. tuberculosis was disaggre-
gated to achieve a single-cell suspension. For this purpose, a bacterial
stock was thawed and centrifuged at 3000 ×g for 8 min and washed
in RPMI medium without antibiotics. The bacterial suspension was
subsequently passed through a 21 G needle (10 times) and then a 1 Gneedle (10 times), followed by sonication for 1 min. Residual clumps
were removed via centrifugation at 500 ×g for 1 min.2.3. THP-1 cell line and MDMs
The human acute monocytic leukemia cell line THP-1 was purchased
from the American Type Culture Collection (TIB202, ATCC, Rockville,MD,
USA). THP-1 cells were grown in RPMI-1640 medium supplemented
with 2 mM L-glutamine, 10 mM HEPES buffer, 1 mM sodium pyruvate
(Lonza), 10% heat-inactivated fetal bovine serum (HycloneTM, Logan,
USA) and 50 μM β-2-mercaptoethanol (Bio-Rad Laboratories, Berkeley,
CA, USA). Cultures were continuously maintained at a cell density be-
tween 0.2 × 106 and 1 × 106 cells/mL. To induce differentiation of cells
to macrophages, THP-1 cells (0.15 × 106 cells/well) were cultured on
96-well plates using 50 nM phorbol 12-myristate 13-acetate (PMA,
Sigma-Aldrich). After 3 days, medium was removed, and fresh medium
was immediately added. The cells were incubated in control medium
by 4 h before any treatment [29].
MDMs were obtained from peripheral blood mononuclear cells
(PBMCs) through the centrifugation of buffy coats from healthy blood
bank donors at the Instituto Nacional de Enfermedades Respiratorias
(INER) under approbation of the Institutional Ethical Review Board of
INER. Heparinized blood was diluted 1:1 with RPMI and centrifuged at
300 ×g for 45 min at room temperature over lymphocyte separation
solution (Lonza) [30]. The layer containing PBMCs was harvested and
monocytes were enriched by plastic adherence. PBMCs were plated on
100 mm Petri dishes (Costar, NY USA) and incubated for 1 h at 37 °C,
in 5% CO2. After discarding non-adherent cells and three washings, the
monocytes (MN) were recovered. The viability of MN as assessed by
Trypan blue exclusion was higher than 98%. MN concentrations were
adjusted to 1 × 106 cells/mL and cultivated in RPMI 1640 supplemented
with 200 mM L-glutamine, and 10% heat-inactivated human serum 24-
well plates (1 × 106 cells/well) at 37 °C, in 5% CO2 for 7 days. By this
time, the cells had acquired macrophage morphology [31,32].2.4. THP-1 cell viability
The cells were seeded at a density 0.15 × 106 cells/well in 96-well
plates in culture medium and differentiated with PMA over three days.
The cells were either infected or left as uninfected controls, and NDGA
or α-mangostin were immediately added to the cells. The cells were
then incubated for ﬁve days and to avoid exhaustion of stimuli in medi-
um, it was replaced twice during incubation period at days 2 and 4 with
media containing freshly prepared stimuli. After incubation, cell viability
was quantiﬁed using a colorimetric assay based on metabolic activity
(Cell Titer 96 Aqueous One Solution distributed by Promega, Madison,
WI, USA), according to the manufacturer's instructions.2.5. Evaluation of NDGA and α-mangostin antimycobacterial activity in
bacterial cultures
For these assays, NDGA orα-mangostin endotoxin free were added at
concentrations ranging from 1000 to 1.0 μg/mL, and eachwell was inocu-
latedwith a bacterial suspension at a concentration of 105 colony-forming
units (CFUs)/mL for total volume of 200 μL. The plates were incubated for
7 days at 37 °C. Subsequently, the CFUs were counted as previously
described [33], and theminimum inhibitory concentration (MIC)was de-
termined. No inhibitory effectswere observed in the presence of DMSO at
the concentration used in these assays (b1.25%). Rifampicin at 0.4 μg/mL
(Sigma-Aldrich) was employed as a reference bactericidal drug for
M. tuberculosis.
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The infection of differenced THP-1 cells (0.15 × 106/well on the 96-
well plate) and MDMs (1.0 × 106/well on the 24-well plate) were per-
formed using bovine serum-opsonizedM. tuberculosis at a multiplicity
of infection (MOI) of 1:10 in RPMI medium without antibiotics. After
1.5 h of incubation at 37 °C in a 5% CO2 atmosphere, the cells were
washed to remove non-internalized bacteria. Immediately after, cells
were stimulated with freshly prepared NDGA,α-mangostin, or rifampi-
cin diluted in RPMI medium containing 10% of heat-inactivated human
serum at declared concentrations, and incubated at 37 °C in 5% CO2 for
ﬁve days. To avoid exhaustion of stimuli in medium, it was replaced
twice during incubation period at days 2 and 4. After the indicated
period of time, the intracellular bacteria were quantiﬁed. The cells
were disruptedwith 0.1% SDS for 10min and then neutralized via the ad-
dition of 10% BSA. Then, the bacteriawere quantiﬁed by CFUs counting or
M. tuberculosis viability was assessed by real time PCR-based method
[34], which compares 16S RNA levels with genomic DNA (IS6110) levels
as an indicator of bacterial growth. Total RNA was isolated from cell ly-
sates by disruption with small glass beads [35] in the presence of TRIzol
reagent (Life Technologies, CA, USA) followed by RNA cleanup using an
RNeasy Miniprep Kit (QIAGEN, CA, USA). cDNA was synthesized using
the Script cDNA Synthesis kit (Bio-Rad, Hercules, CA, USA) according to
the manufacturer's instructions. The relative 16S values were calculated
usingΔΔCT analysis, with the IS6110 value serving as the “housekeeping
gene”. The following IS6110 genomic element and 16S primer sequences
were used: 16S Forward 5′-GGTGCGAGCGTTGTCCGGAA-3′, 16S Reverse
5′-CGCCCGCACGCTCACAGTTA-3′ and IS6110 Reverse 5′-TCTTGTATAG
GCCGTTGATCGTCT-3′ [34].2.7. Autophagy inhibition
Additionally, we evaluated the effect of autophagy inhibitors (SB and
wortmannin) on survival of M. tuberculosis in THP-1 cells and MDMs.
After the time of infection and removed non-internalized bacteria, the
cells were incubated with SB (10 μM) or wortmannin (100 nM) by
0.5 h and then NDGA was added. Finally, the cells were incubated for
3 days, lysed and the intracellular bacteria were quantiﬁed by CFUs
and, real time PCR-based method.Fig. 1. Inhibitory effects of NDGA andα-mangostin onM. tuberculosis growth. Bacteriawere cult
7 days. CFUswere quantiﬁed by counting the number of surviving bacteria for each concentratio
to cells treated with media alone.2.8. LC3 immunoﬂuorescent staining
For microscopy experiments, 1 × 105 cells/well in 500 μL of RPMI
medium were cultivated in an 8-well Lab-Tak II chamber. After the
cells were infectedwithM. tuberculosis expressing themCherry ﬂuores-
cent protein and subjected to NDGA or α-mangostin treatment, they
were stimulated as described above. Next, the cells were ﬁxed with 4%
paraformaldehyde, stained with rabbit anti-LC3B (Enzo Life Sciences,
NY, USA) and visualized with Fluorescein Isothiocyanate (FITC).
Counter-staining with Hoechst (Enzo Life Sciences) to detect nuclei
was performed following themanufacturer's instructions. Cells were vi-
sualized under a ﬂuorescence AxioScope.A1 microscope (Carl Zeiss,
Oberkochen, Germany), and images were acquired and analyzed with
ZEN Pro software (Carl Zeiss) [36].
2.9. Measurement of TNF-α
Infected THP-1 cells and MDMs were treated with NDGA and
autophagy inhibitors (wortmannin or SB). Culture medium alone was
used as a negative control and supernatants of treated cells were
harvested and frozen at−20 °C. TNF-α production was determined in
24 h culture supernatants using an enzyme-linked immunosorbent
assay (ELISA) previously described [37]. Absorbance was read on an
HT Multi-Mode Microplate Reader (Biotek, WA, USA) at 450 nm. The
results are presented as the mean value for duplicate wells in three
independent experiments.
2.10. Statistical analyses
Statistical analyses were performed with GraphPad Prism through
analysis of variance (ANOVA) with Dunnett's multiple comparison
tests for THP-1 cell line and Friedman's multiple comparison tests for
MDMs. p ≤ 0.05 was considered statistically signiﬁcant.
3. Results
3.1. NDGA and α-mangostin show inhibitory activity against the growth of
M. tuberculosis
First, we evaluated the effect of NDGA onM. tuberculosis growth and
determined that this compound caused a dose-dependent decrease in
bacterial growth at doses from 8 to 250 μg/mL when the bacteria were
cultured in liquid medium (Fig. 1A). The bactericidal effect of NDGA
was compared with those of rifampicin (0.4 μg/mL) and α-mangostin,ivated in 7H9Middlebrookmedium supplementedwith NDGA (A) orα-mangostin (B) for
n of compounds. The presented data represent themean± SE (n=4). *p b 0.05 compared
Fig. 2. Effect of NDGA (7 μg/mL) andα-mangostin (6 μg/mL) on the viability of THP-1macrophages thatwere left uninfected (A) or infectedwithM. tuberculosisH37 Ra (B). Data represent
the mean ± SE (n = 4). *p b 0.05 compared to the untreated cells.
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ity (Fig. 1B) [38]. The obtainedMICswere 250 μg/mL and 62.5 μg/mL for
NDGA and α-mangostin, respectively.3.2. Effect of NDGA and α-mangostin on THP-1 cell viability
NDGA did not signiﬁcantly decrease THP-1 cell viability in either
infected or uninfected cells after 5 days of incubation; however, α-
mangostin promoted cell death under both conditions. The viability of
the infected cells was decreased signiﬁcantly after 3 and 5 days of incu-
bation,while the viability of uninfected cells was reduced after 5 days of
incubation. In addition, the infected cells that received no treatment
(medium) showed a slight decrease in viability after 5 days of incuba-
tion (Fig. 2A-B).Fig. 3. Intracellular antimicrobial activity of NDGA andα-mangostin againstM. tuberculosis
in THP-1 macrophages. NDGA (7 μg/mL) andα-mangostin (6 μg/mL) were added 1 h after
infection. CFUs were quantiﬁed by counting the numbers of surviving bacteria at each time
point. The presented data represent themean± SE (n=4). *p b 0.05, signiﬁcant difference
of each treatment (RIF, NDGA or α-mangostin) with respect to cells treated with medium
only.3.3. NDGA and α-mangostin inhibit the intracellular growth of
M. tuberculosis in THP-1 cells
We found that post-infection treatment with NDGA or α-mangostin
endotoxin free decreased the mycobacterial burden in THP-1 cells
in comparison with untreated cells after 3 and 5 days of incubation
(Fig. 3). However, neither NDGA nor α-mangostin were capable of
completely inhibit the growth of bacteria in a manner comparable to ri-
fampicin. Intracellular bacterial growth was signiﬁcantly decreased in
THP-1 cells treated with NDGA or α-mangostin (p b 0.05, 75% and 50%,
respectively) in comparison with medium after 5 days of incubation.
Treatment with rifampicin resulted in a signiﬁcant bactericidal effect of
more than 98% throughout the incubation period.
3.4. NDGA and α-mangostin induce autophagy in THP-1 cells
During autophagocytosis, the LC3 protein migrates from the intra-
cellular cytoplasm to autophagic vesicles; thus, concentrated vesicles
containing ﬂuorescent LC3 indicate autophagy [39]. NDGA (7 μg/mL)
increased the percentage of cells showing LC3 expression (80%) with
respect to the medium alone (26%) (Fig. 4A-C). Fluorescence microsco-
py revealed a visible increase in the number and size of intracellular
autophagic vesicles in the cells treated with NDGA. The treated cells
exhibited an average of 18 puncta, while the control only resulted in
approximately 9 puncta per cell (Fig. 4C). In addition, we demonstrated
that α-mangostin (6 μg/mL) induced autophagy in THP-1 cells. Under
these conditions, 84% of the cells showed autophagosome formation,
and the average number of puncta per cell was 20. We also evaluated
the effect of post-treatmentwith NDGA andα-mangostin on autophagy
in macrophages infected with M. tuberculosis. These cells showed
signiﬁcant increment in the number of vesicles and in the detection
of bacteria within autophagic vesicles with respect to the control
(70% and 78% of cells with vesicles, under treatment with NDGA and
α-mangostin, respectively) (Fig. 5A-C).
3.5. Autophagy inhibition decreased antimicrobial activity of NDGA in
macrophages infected with M. tuberculosis
To investigate the role of the interaction between antimicrobial
activity and autophagy induced by NDGA. THP-1 cells and MDMs
were infected, and then treated with SB or wortmannin for 0.5 h and
immediately NDGA added and incubated for 24 h. As shown, the treated
THP-1 cells withWor S plus NDGA signiﬁcantly diminished LC-3II accu-
mulation (p b 0.05, 30% and 22% respectively) compared toNDGA alone.
We also evaluated the effect of the autophagy inhibitors on intracellular
survival of M. tuberculosis. We observed that antimicrobial activity
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SB after 3 days of incubation (Fig. 6D). Similarly, we evaluated the effect
of autophagy inhibitors in MDMs infected withM. tuberculosis and ob-
served that antimicrobial activity induced by NDGA was decreased
after treatment with wortmannin (Fig. 6E). In addition TNF-α levels
were assessed in supernatants from infected THP-1 cells and MDMs
treated with NDGA and with autophagy inhibitors (wortmannin and
SB). We observed that the TNF-α production was signiﬁcantly lower
in cells treated with NDGA in comparison to medium and thatFig. 4. NDGA and α-mangostin induced autophagy. Cells were stimulated with 7 μg/mL NDGA
ﬂuorescence microscopy using an anti-human LC3-FITC antibody; images acquired at 1000×
minimum of 80 cells for each condition. (C) The number of puncta per cell was counted in a
(NDGA or α-mangostin) with respect to cells treated with medium only.autophagy inhibitors did not restore the effect caused by NDGA
(Fig. 6C) in both cells THP-1 and MDMs.
4. Discussion
According to the WHO, more than 75% of the world's population
employs plants as a form of health care [40,41]. In fact, there are 350
described species of plants used around the world for the treatment of
TB, including L. tridentata [8,15]. It is noteworthy that a number of
compounds with distinct biological activities have been isolated fromor 6 μg/mL α-mangostin for 24 h. (A) Detection of autophagosomes was performed via
are shown. (B). The percentage of cells with LC3+ puncta was assessed by counting a
t least 25 of the cells showing puncta. *p b 0.05, signiﬁcant difference of each treatment
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antimycobacterial activity and cytotoxicity in infected or uninfected
THP-1 cells. First, based on the results obtained using the CFU counting,
we demonstrated that NDGA had an inhibitory effect onM. tuberculosis.
The results showed that NDGA partially decreased bacterial growth
in vitro at concentrations ranging from 8 to 125 μg/mL, and exerted a
complete bactericidal effect onM. tuberculosis at 250 μg/mL. This activity
may be related to the structural similarity of this compound with
ﬂavonoids, as there is evidence that some ﬂavonoids, such as butein
and isoliquiritigenin, exhibit complex structures that destabilize the
bacterial cell wall and inhibit the synthesis of fatty acids and mycolic
acids [43,44]. Additionally, it has been reported that some phenols,
such as meso-dihydroguaiaretic acid, that are similar to NDGA can in-
hibit the enzyme carbonic anhydrase, which is involved in carbonFig. 5. NDGA and α-mangostin induced autophagy in infected THP-1 macrophages andM. tub
stimulated with 7 μg/mL NDGA or 6 μg/mLα-mangostin for 24 h. (A) Detection of autophagoso
M. tuberculosis detection was conducted based on the expression of the mCherry ﬂuorescent pr
was assessed by counting aminimumof 80 cells in each condition. (C) Percentage of bacteria co
the cells showing puncta. *p b 0.05, signiﬁcant difference of each treatment (NDGA or α-mangmetabolism, and the coenzyme A transferase ofM. tuberculosis [45,46],
potentially preventing bacterial growth in vitro.
It has been reported that several xanthones isolated from the fruit
hull of G. mangostana, such as α- and β-mangostins and garcinone B,
exert an inhibitory effect against M. tuberculosis [13]. In our assay, we
demonstrated that α-mangostin decreased mycobacterial growth at a
concentration of 25 μg/mL. It was previously shown that α-mangostin
quickly disrupted the bacterial wall of Staphylococcus aureus, leading
to the loss of intracellular components, and it is possible that this
compound interacts directly with the bacterial membrane, provoking
membrane disruption and bactericidal action [47]. In addition, it has
been observed that α-mangostin can inhibit enzymes involved in
glycolysis, such as aldolase, glyceraldehyde-3-phosphate dehydroge-
nase and lactate dehydrogenase, in Streptococcus mutans [48]. In this
context, α-mangostin could dilute lipophilic substances such as wallerculosis is localized in autophagosomes. Cells were infected withM. tuberculosis and then
mes was performed via ﬂuorescence microscopy using an anti-human LC3-FITC antibody.
otein, and images were acquired at 1000×. (B) The percentage of cells with LC3+ puncta
localizing with LC3 are shown. The number of puncta per cell was counted in at least 25 of
ostin) with respect to cells treated with medium only.
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M. tuberculosis, thus preventing bacterial growth.
We found that 7 μg/mL NDGA and 6 μg/mLα-mangostin signiﬁcantly
decreased the intracellular growth of M. tuberculosis. These results
suggest that these two compounds could have inhibitory effects
through two different mechanisms. High concentrations of NDGA or
α-mangostin directly prevented the growth of M. tuberculosis, and
the possible mechanisms were discussed above. However, lower con-
centrations of these compounds prevented the intracellular growth of
the bacteria in macrophages, and these effects may have been due to
stimulatory effects of NDGA or α-mangostin on the immune response
in human macrophages.
Recently, autophagy has been identiﬁed as a mechanism to restrict
mycobacterial proliferation in human macrophages [49]. Our resultsFig. 6. Autophagy Inhibition decreased antimicrobial activity of NDGA in infected cells. THP-1 c
(W)wortmanin, and (SB) SB203580were added and incubated for 0.5 h, then 7 μg/mL NDGAw
ﬁxed and stainedwith anti-LC3-FITC;Hoeschtwas used to stain the nuclei. Detection of autopha
B)Graphics show thepercentage of THP-1 cellswith puncta LC3upon the indicated treatments.
D)Mycobacterial growthwasquantiﬁedby CFUs at 3 days of incubation in THP-1macrophages a
MDMs. Data represent the mean ± SE (n = 3). *p b 0.05, signiﬁcant difference of each treatmshowed that α-mangostin induce autophagy in uninfected or infected
THP-1 cells after 24 h of treatment and the autophagic vesicle
colocalization with mycobacteria. However, after 3 days of incubation,
treatment with α-mangostin resulted in the death of the infected
cells, most likely through autophagy. It has been reported that α-
mangostin can induce autophagy and autophagic cell death in mouse
intestinal epithelial cells, GFP-LC3 transgenicmice [50], human glioblas-
toma cells [25] and CML cell lines [26].
To our knowledge, this is the ﬁrst report of autophagy induction and
antimycobacterial activity by NDGA. Our results also showed that treat-
ment with the autophagy inhibitors wortmannin (PI3K inhibitor) and
SB (p38 inhibitor), resulted in a marked increase in bacterial load and
signiﬁcant decrease of LC3-II puncta formation in THP-1 cells and
MDMs. Therefore, our results suggest that NDGA induces autophagyells and MDMs were infected withM. tuberculosis at an MOI of 10 and incubated for 24 h.
as added and incubated for additional 24 h. A) THP-1 cells (top) andMDMs (bottom)were
gosomeswas performed via ﬂuorescencemicroscopy and imageswere acquired at 1000×.
C) TNF-α levelswere assessed in 24h in supernatants from infected THP-1 cells andMDMs.
nd E)Mycobacterial growthwas assessed by rRNA16S expression at 1 day of incubation in
ent (W, SB or medium) in comparison to cells treated with NDGA alone.
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MDMs and that autophagy is related to cytotoxic mechanisms against
Mycobacteria. It is well known that autophagy is not the only bacteri-
cidal mechanism that is inhibited by wortmanin and SB, because both
compounds inhibit phagosome lysosome fusion [51-53]. In fact, cells
treatedwith these inhibitors and NDGA reached a highermycobacterial
load compared to non-treated cells, while the LC3II puncta counts were
reestablished to the control level (cells cultured in medium). The exac-
erbated bacterial growth detected in our results could also be due to the
blockade of phagosome maturation by wortmannin and SB in addition
to autophagy inhibition.
Furthermore, in a breast cancer model, it has been demonstrated
that NDGA inhibits one of themain regulatory mechanisms of autopha-
gy such as the mammalian target of rapamycin complex 1 (mTORC1)
through disruption of mTOR–Raptor complex preventing cell prolifera-
tion [54].Moreover, it has been reported that themainNDGAantioxidant
properties rest on the nuclear translocation of Nrf2 and consequently the
release of Kelch-like ECH-associated protein 1 (Keap1) [55-56], and
the interaction of p62 with Keap1 increases the autophagic ﬂux and
that the downregulation of Keap1 decreases the autophagy levels [57].
Therefore, it is possible that NDGA exerts different mechanisms involved
in autophagy induction in macrophages.
In addition, we observed that NDGA treatment decreases TNF-α
production and that the inhibition with wortmannin and SB did not
restore the effect caused by NDGA. In this regard it has been reported
that the treatment with NDGA exerts an anti-inﬂammatory effect in
THP-1 cells by decreasing lipoxygenase activity, which in turn decreases
TNF-α production [20]. Therefore we speculate that reduction of TNF-α
by NDGA could be a mechanism independent of autophagy induction
and could prevent the exacerbation of inﬂammation and contribute to
the elimination of intracellular bacteria.
Our study suggests the potential use of NDGA as adjunctive therapy
for tuberculosis treatment. Regarding theNDGA toxicity in humans, this
compound has been tested for prostate cancer therapy; the daily and
continuous administration of NDGA (≤2250 mg) for 28 days was rea-
sonably well tolerated, only some patients presented fatigue, diarrhea,
nausea, dizziness and headache. In contrast, the continuous administra-
tion of NDGA for more of 18 weeks was slightly toxic, 60% of patients
showed high transaminase levels, a marker of liver damage [58-59].
Additional studies are required to determine the optimum concentra-
tion to obtain the desirable immunomodulatory effects in tuberculosis
treatment without the possible adverse effects.
In conclusion, high concentrations of NDGA and α-mangostin
inhibited the growth ofM. tuberculosis and low concentrations simulta-
neously prevented intracellular bacterial growth in humanmacrophages.
Theseﬁndings allowus to suggest that these compounds could be used in
combination with INH and RIF and may contribute to the treatment of
drug-resistant tuberculosis.
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